Uncovering the Potential of CD40 Agonism to Enhance Immune Checkpoint Blockade-Reference-Cited by-同舟云学术

Uncovering the Potential of CD40 Agonism to Enhance Immune Checkpoint Blockade

Published:2023-10-23 Issue:1 Volume:30 Page:9-11
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:

Author:

Wu Richard C.¹^ORCID,Luke Jason J.²^ORCID

Affiliation:

1. 1The Ohio State University James Comprehensive Cancer Center and Division of Medical Oncology, Columbus, Ohio.

2. 2UPMC Hillman Cancer Center and the University of Pittsburgh Department of Medicine, Pittsburgh, Pennsylvania.

Abstract

Summary In this CCR Translations, we discuss the therapeutic potential of CD40 agonism, which stimulates antigen-presenting cells (APC) to activate effector T and NK cells. CD40 agonism may lead to development of an interferon-activated, T cell–inflamed tumor microenvironment and has the potential to facilitate long-term response with immune checkpoint blockade. See related article by Weiss et al., p. 74

Funder

National Cancer Institute

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Link

https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-23-2437/3375936/ccr-23-2437.pdf

Reference14 articles.

1. A phase II trial of the CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti–PD-1 therapy;Weiss;Clin Cancer Res,2024

2. Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067;Hodi,2022

3. The calm after the cytokine storm: lessons from the TGN1412 trial;St Clair;J Clin Invest,2008

4. The emerging landscape of novel 4–1BB (CD137) agonistic drugs for cancer immunotherapy;Claus;MAbs,2023

5. Agonistic CD40 Antibodies in Cancer Treatment;Djureinovic;Cancers,2021